Abstract:Background: COVID-19 is a viral respiratory disease caused by the severe acute respiratory Syndrome-Coronavirus type 2 (SARS-CoV-2). Patients with this disease may be more prone to venous or arterial thrombosis because of the activation of many factors involved in it, including inflammation, platelet activation and endothelial dysfunction. Therefore, this study focused on coagulation and thrombosis-related indicators in COVID-19, with the hope to find biomarkers that can predict patients' outcome. Methods: This is a retrospective single-center study involving 74 severe and critically ill COVID-19 patients recruited from the ICU department of the Tongji Hospital in Wuhan, China. The patients were divided into two groups: severe patients and critically ill patients. The serum IP-10, MCP-1 and MIP1a level in both groups was detected using the enzyme-linked immunosorbent assay (ELISA) kit. The clinical symptoms, laboratory test results and the outcome of COVID-19 patients were retrospectively analyzed. Results: The serum IP-10 and MCP-1 level in critically ill patients was significantly higher than that in severe patients ( P <0.001). However, no statistical difference in MIP1a between the two groups was found. The analysis of dynamic changes showed that these indicators remarkably increased in patients with poor prognosis. Since the selected patients were severe or critically ill, no significant difference was observed between survival and death. Conclusions: IP-10 and MCP-1 are biomarkers predicting the severity of COVID-19 disease and could be related to the risk of death in COVID-19 patients. In addition, anti-IP-10 antibody treatment may represent a new approach in COVID-19 patients, especially the ones with thrombotic events.Funding Statement: This research was supported by the grants from the National Natural Science Foundation of China (Grants 81671618 and 81871302), CAMS Innovation Fund for Medical Sciences (CIFMS 2017-I2M-3- 001 and CIFMS 017-I2M-B&R-01).Declaration of Interests: The authors declare no conflicts of interest.Ethics Approval Statement: This study was approved by the Ethics Committee of the Peking Union Medical College Hospital, and the informed consent to participate to this study was provided by all the enrolled patients or their families.

Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID‐19 patients

The proteomic characteristics of airway mucus from critical ill COVID-19 patients

IP-10 and MCP-1 As Biomarkers Predicting Disease Severity of COVID-19

Dynamics of the Upper Respiratory Tract Microbiota and Its Association with Fatality in COVID-19 Patients

Airway mucins promote immunopathology in virus-exacerbated chronic obstructive pulmonary disease

Expression and Clinical Significance of Mucoprotein MUC5AC in Patients with Chronic Obstructive Pulmonary Disease

Biochemical, biophysical, and immunological characterization of respiratory secretions in severe SARS-CoV-2 infections

MUC5AC drives COPD exacerbation severity through amplification of virus-induced airway inflammation

Biochemical, Biophysical, and Immunological Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections

Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19

Effects of the Lower Airway Secretions on Airway Opening Pressures and Suction Pressures in Critically Ill COVID-19 Patients: A Computational Simulation

Gut Mycobiota Alterations in Patients with COVID-19 and H1N1 Infections and Their Associations with Clinical Features

The Characteristics and Clinical Significance of Mucin Levels in Bronchoalveolar Lavage Fluid of Patients with Interstitial Lung Disease.

Elevated Serum Levels Of Mucin-Associated Antigen In Patients With Acute Respiratory Distress Syndrome

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Potential Mechanisms for Traditional Chinese Medicine in Treating Airway Mucus Hypersecretion Associated With Coronavirus Disease 2019

Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection

A computational simulation of the effect of alveolar exudates properties on airway opening pressure in patients with COVID-19

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Dynamic Alterations in the Respiratory Tract Microbiota of Patients with COVID‐19 and its Association with Microbiota in the Gut

The characteristics of microbiome in the upper respiratory tract of COVID-19 patients